{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:18:38Z","timestamp":1757618318393,"version":"3.44.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Macau Science and Technology Development Fund","award":["0071\/2024\/RIA1"],"award-info":[{"award-number":["0071\/2024\/RIA1"]}]},{"name":"University of Macau Multi-Year Research Gran","award":["MYRG-GRG2023-00077-ICMS-UMDF"],"award-info":[{"award-number":["MYRG-GRG2023-00077-ICMS-UMDF"]}]},{"name":"Dr. Stanley Ho Medical Development Foundation","award":["SHMDF-VSEP\/2024\/001"],"award-info":[{"award-number":["SHMDF-VSEP\/2024\/001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40262-025-01523-2","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T05:44:10Z","timestamp":1749879850000},"page":"1203-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determining the Optimal Dosing of Methyldopa in Pregnancy-Induced Hypertension Using PBPK-PD Modeling"],"prefix":"10.1007","volume":"64","author":[{"given":"Xinyang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-4773","authenticated-orcid":false,"given":"Defang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"1523_CR1","doi-asserted-by":"publisher","DOI":"10.4314\/ejhs.v29i1.4","author":"TA Gudeta","year":"1970","unstructured":"Gudeta TA, Regassa TM. Pregnancy induced hypertension and associated factors among women attending delivery service at Mizan-Tepi University Teaching Hospital, Tepi General Hospital and Gebretsadik Shawo Hospital, Southwest, Ethiopia. Ethiop J Health Sci. 1970. https:\/\/doi.org\/10.4314\/ejhs.v29i1.4.","journal-title":"Ethiop J Health Sci"},{"issue":"1","key":"1523_CR2","first-page":"77","volume":"39","author":"AM Khedagi","year":"2021","unstructured":"Khedagi AM, Bello NA. Hypertensive disorders of pregnancy. Cardiol Clin. 2021;39(1):77\u201390.","journal-title":"Cardiol Clin"},{"issue":"2","key":"1523_CR3","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1161\/HYP.0000000000000208","volume":"79","author":"VD Garovic","year":"2022","unstructured":"Garovic VD, Dechend R, Easterling T, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022;79(2):e21\u201341.","journal-title":"Hypertension"},{"issue":"4","key":"1523_CR4","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3390\/ijerph20042994","volume":"20","author":"K-J Chang","year":"2023","unstructured":"Chang K-J, Seow K-M, Chen K-H. Preeclampsia: recent advances in predicting, preventing, and managing the maternal and fetal life-threatening condition. IJERPH. 2023;20(4):2994.","journal-title":"IJERPH."},{"key":"1523_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","volume":"27","author":"LA Magee","year":"2022","unstructured":"Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148\u201369.","journal-title":"Pregnancy Hypertens."},{"issue":"1","key":"1523_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajog.2021.02.032","volume":"225","author":"BD Wesley","year":"2021","unstructured":"Wesley BD, Sewell CA, Chang CY, Hatfield KP, Nguyen CP. Prescription medications for use in pregnancy\u2014perspective from the US Food and Drug Administration. Am J Obstet Gynecol. 2021;225(1):21\u201332.","journal-title":"Am J Obstet Gynecol"},{"issue":"59","key":"1523_CR7","first-page":"009","volume":"1","author":"A Riad","year":"2021","unstructured":"Riad A. Treatment of gestational hypertension with oral labetalol and methyldopa in Iraqi pregnant women. GinPolMedProject. 2021;1(59):009\u201313.","journal-title":"GinPolMedProject."},{"issue":"3","key":"1523_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/uog.20137","volume":"54","author":"VA Lopes Van Balen","year":"2019","unstructured":"Lopes Van Balen VA, Van Gansewinkel TAG, De Haas S, et al. Maternal kidney function during pregnancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2019;54(3):297\u2013307.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"5","key":"1523_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/AOG.0000000000002579","volume":"131","author":"DM Haas","year":"2018","unstructured":"Haas DM, Marsh DJ, Dang DT, et al. Prescription and other medication use in pregnancy. Obstet Gynecol. 2018;131(5):789\u201398.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"1523_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ajog.2022.07.037","volume":"227","author":"CA Sewell","year":"2022","unstructured":"Sewell CA, Sheehan SM, Gill MS, et al. Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials. Am J Obstet Gynecol. 2022;227(6):805\u201311.","journal-title":"Am J Obstet Gynecol"},{"issue":"suppl_7","key":"1523_CR11","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.1093\/cid\/ciu709","volume":"59","author":"JS Sheffield","year":"2014","unstructured":"Sheffield JS, Siegel D, Mirochnick M, et al. Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014;59(suppl_7):S437\u201344.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1523_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","volume":"122","author":"JH Kim","year":"2011","unstructured":"Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011;122(1):1\u20136.","journal-title":"Toxicol Sci"},{"issue":"3","key":"1523_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/bcp.12207","volume":"77","author":"AB Ke","year":"2014","unstructured":"Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19: PBPK prediction of PK changes during pregnancy. Br J Clin Pharmacol. 2014;77(3):554\u201370.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1523_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/psp4.12274","volume":"7","author":"AB Ke","year":"2018","unstructured":"Ke AB, Greupink R, Abduljalil K. Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations: PBPK modeling in pregnancy. CPT Pharmacometr Syst Pharmacol. 2018;7(2):103\u201310.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"1","key":"1523_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11095-023-03638-2","volume":"41","author":"X Liu","year":"2024","unstructured":"Liu X, Wang W, Chen J, Chen D, Tao Y, Ouyang D. PBPK\/pd modeling of nifedipine for precision medicine in pregnant women: enhancing clinical decision-making for optimal drug therapy. Pharm Res. 2024;41(1):63\u201375.","journal-title":"Pharm Res"},{"issue":"7","key":"1523_CR16","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s11095-023-03523-y","volume":"40","author":"Y Song","year":"2023","unstructured":"Song Y, Wang W, Liu X, et al. Physiologically based pharmacokinetic modeling for multiple oral administration labetalol in pregnant women. Pharm Res. 2023;40(7):1765\u201375.","journal-title":"Pharm Res"},{"key":"1523_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2125.1978.tb04609.x","volume":"6","author":"HMR Jones","year":"1978","unstructured":"Jones HMR. A Study of the transfer of a-methyldopa to the human foetus and newborn infant. Br J Clin Pharmacol. 1978;6:432.","journal-title":"Br J Clin Pharmacol"},{"key":"1523_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2125.1979.tb01022.x","volume":"8","author":"HMR Jones","year":"1979","unstructured":"Jones HMR, Cummings AJ, Setchell KDR, Lawson AM. A study of the disposition of alpha-methyldopa in newborn infants following its administration to the mother for the treatment of hypertension during pregnancy. Br J Clin Pharmacol. 1979;8:433\u201340.","journal-title":"Br J Clin Pharmacol"},{"key":"1523_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194957","author":"N Campbell","year":"1995","unstructured":"Campbell N, Robertson S, Burgess E, Skerjanec A, Tam Y. Methyldopa kinetics before and after ingestion of methyldopa for eight weeks. Eur J Clin Pharmacol. 1995. https:\/\/doi.org\/10.1007\/BF00194957.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1523_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1161\/01.CIR.28.4.492","volume":"28","author":"A Sjoerdsma","year":"1963","unstructured":"Sjoerdsma A, Vendsalu A, Engelman K, Watts MD. Studies on the metabolism and mechanism of action of methyldopa. Circulation. 1963;28(4):492\u2013502.","journal-title":"Circulation"},{"issue":"3","key":"1523_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/j.1552-4604.1995.tb04058.x","volume":"35","author":"A Skerjanec","year":"1995","unstructured":"Skerjanec A, Campbell NRC, Robertson S, Tam YK. Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. J Clin Pharmacol. 1995;35(3):275\u201380.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1523_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1570-0232(01)00612-2","volume":"768","author":"CH Oliveira","year":"2002","unstructured":"Oliveira CH, Barrientos-Astigarraga RE, Sucupira M, Graudenz GS, Muscar\u00e1 MN, De Nucci G. Quantification of methyldopa in human plasma by high-performance liquid chromatography\u2013electrospray tandem mass spectrometry. J Chromatogr B. 2002;768(2):341\u20138.","journal-title":"J Chromatogr B"},{"key":"1523_CR23","doi-asserted-by":"publisher","DOI":"10.4172\/jbb.1000291","author":"AL Khokhlov","year":"2016","unstructured":"Khokhlov AL, Shitov LN. The pharmacokinetic properties and bioequivalence of methyldopa formulations: results of an open-label, randomized, two-period, crossover, single-dose study. J Bioequiv Availab. 2016. https:\/\/doi.org\/10.4172\/jbb.1000291.","journal-title":"J Bioequiv Availab"},{"issue":"10","key":"1523_CR24","first-page":"607","volume":"60","author":"H Valizadeh","year":"2010","unstructured":"Valizadeh H, Nemati M, Hallaj-Nezhadi S, Ansarin M, Zakeri-Milani P. Single dose bioequivalence study of a-methyldopa tablet formulations using a modified HPLC method. CNS Active Drugs. 2010;60(10):607\u201311.","journal-title":"CNS Active Drugs."},{"issue":"1","key":"1523_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/01.HYP.8.1.16","volume":"8","author":"A Bobik","year":"1986","unstructured":"Bobik A, Jennings G, Jackman G, Oddie C, Korner P. Evidence for a predominantly central hypotensive effect of alpha-methyldopa in humans. Hypertension. 1986;8(1):16\u201323.","journal-title":"Hypertension"},{"issue":"2","key":"1523_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF00645132","volume":"12","author":"E Stenbeak","year":"1977","unstructured":"Stenbeak E, Myhre H. Pharmacokinetics of methyldopa in healthy man. Eur J Clin Pharmacol. 1977;12(2):117\u201323.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1523_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2125.1983.tb02147.x","volume":"16","author":"A Renwick","year":"1983","unstructured":"Renwick A, Higgins V, Powers K, Smith C, George C. The absorption and conjugation of methyldopa in patients with coeliac and Crohn\u2019s diseases during treatment. Brit J Clin Pharmacol. 1983;16(1):77\u201383.","journal-title":"Brit J Clin Pharmacol"},{"key":"1523_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0022-3565(25)30593-8","volume":"198","author":"KC Kwan","year":"1976","unstructured":"Kwan KC, Foltz EL, Breault GO, Baer JE, Totaro JA. Pharmacokinetics of methyldopa in man. J Pharmacol Exp Ther. 1976;198:264\u201377.","journal-title":"J Pharmacol Exp Ther"},{"key":"1523_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1365-2125.1982.tb01967.x","volume":"14","author":"G Mwaluko","year":"1982","unstructured":"Mwaluko G, Weinshilboum R. alpah-methyldopa, alpha-methyldopamine and alpha-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase. Br J Clin Pharmacol. 1982;14:231\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1523_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/psp4.12300","volume":"7","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Solodenko J, Ince I, Eissing T. Applied concepts in PBPK modeling how to extend an open systems pharmacology model to the special population of pregnant women. CPT Pharmacometr Syst Pharmacol. 2018;7:419\u201331.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1523_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04784.x","author":"G Lamming","year":"1979","unstructured":"Lamming G, Symonds E. Use of labetalol and methyldopa in pregnancy-induced hypertension. Brit J Clin Pharmcol. 1979. https:\/\/doi.org\/10.1111\/j.1365-2125.1979.tb04784.x.","journal-title":"Brit J Clin Pharmcol"},{"issue":"4","key":"1523_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1365-2796.1972.tb00062.x","volume":"191","author":"E Myhre","year":"1972","unstructured":"Myhre E, Brodwall EK, Hansen ST. Plasma turnover of methyldopa in advanced renal failure. J Internal Med. 1972;191(4):343\u20137.","journal-title":"J Internal Med"},{"issue":"48","key":"1523_CR33","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.18410\/jebmh\/2019\/631","volume":"6","author":"R Pal","year":"2019","unstructured":"Pal R, Khatoon A. Comparative efficacy of labetalol and methyldopa in the treatment of new onset hypertension during pregnancy. J Evid Based Med Healthc. 2019;6(48):3022\u20135.","journal-title":"J Evid Based Med Healthc"},{"issue":"7233","key":"1523_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(62)91781-6","volume":"1","author":"CT Dollery","year":"1962","unstructured":"Dollery CT, Harington M. Methyldopa in hypertension clinical and pharmacological studies. Lancet. 1962;1(7233):759\u201363.","journal-title":"Lancet"},{"key":"1523_CR35","unstructured":"Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin-clinical management guidelines for Obstetrician\u2013Gynecologists. Obstet Gynecol. No. 202. 2018."},{"issue":"23","key":"1523_CR36","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa055202","volume":"354","author":"WO Cooper","year":"2006","unstructured":"Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443\u201351.","journal-title":"N Engl J Med"},{"key":"1523_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013495","author":"L Malha","year":"2019","unstructured":"Malha L, August P. Safety of antihypertensive medications in pregnancy: living with uncertainty. JAHA. 2019. https:\/\/doi.org\/10.1161\/JAHA.119.013495.","journal-title":"JAHA"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01523-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:27:01Z","timestamp":1757186821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01523-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01523-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"28 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was financially supported by the Macau Science and Technology Development Fund (0071\/2024\/RIA1) and University of Macau Multi-Year Research Gran (MYRG-GRG2023-00077-ICMS-UMDF) and Dr. Stanley Ho Medical Development Foundation \u201cSet Sail for New Horizons, Create the Future\u201d Grant 2024 (SHMDF-VSEP\/2024\/001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xinyang Liu, Wei Wang, Jinying Zhu, Jingsi Chen, Xiaoyi Wang, Dunjin Chen, and Defang Ouyang declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}